Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Present at Jefferies 2014 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , May 28, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4, 2014 at 9 a.m. ET in New York .
View HTML
Toggle Summary Veracyte Presents Preliminary Data for Molecular Classifier to Improve Early, Non-Surgical Diagnosis of Idiopathic Pulmonary Fibrosis
Classifier shows promise for differentiating IPF from other interstitial lung diseases
View HTML
Toggle Summary Veracyte, Inc. Launches Afirma® Malignancy Classifiers to Further Help Thyroid Nodule Patients Avoid Unnecessary Surgeries and Lower Healthcare Costs
SOUTH SAN FRANCISCO, Calif. , May 13, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of its Afirma Malignancy Classifiers to further establish the Afirma Thyroid FNA Analysis as a comprehensive tool for reducing unnecessary surgeries and healthcare costs among the
View HTML
Toggle Summary Veracyte, Inc. Announces First Quarter 2014 Financial Results
-- 1Q Revenue Increased 71%, Compared to Prior Year ---- First Blue Cross Plan Issues Coverage for Afirma® Gene Expression Classifier (GEC); Total Covered Lives Exceeds 125 Million ---- Conference Call and Webcast Today at 5 p.m. ET --
View HTML
Toggle Summary Preliminary Data Supporting Veracyte Molecular Classifier for Idiopathic Pulmonary Fibrosis (IPF) Diagnosis to be Presented at ATS 2014
SOUTH SAN FRANCISCO, Calif. , May 7, 2014 /PRNewswire/ -- Veracyte, Inc . (Nasdaq: VCYT) announced that early data demonstrating the company's ability to develop a molecular classifier differentiating interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), will be
View HTML
Toggle Summary New Data Validating Veracyte's Afirma® Malignancy Classifiers to be Presented at AACE Congress
SOUTH SAN FRANCISCO, Calif. , May 6, 2014 /PRNewswire/ --  Veracyte, Inc . (Nasdaq: VCYT) today announced that four abstracts supporting the use of the company's Afirma Malignancy Classifiers and enhancing its overall Afirma solution will be presented at the American Association of Clinical
View HTML
Toggle Summary Veracyte and Fleury Announce Partnership to Make the Afirma® Gene Expression Classifier Available to Patients in Brazil
SOUTH SAN FRANCISCO , Calif. and SAO PAULO, Brazil , May 2, 2014 /PRNewswire/ --  Veracyte, Inc . (Nasdaq: VCYT) and Fleury Medicine and Health today announced a new partnership that will make Veracyte's Afirma Gene Expression Classifier (GEC) available to patients in Brazil , helping to reduce
View HTML
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss First Quarter 2014 Financial Results on May 8, 2014
SOUTH SAN FRANCISCO, Calif. , May 1, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today that its first quarter 2014 financial results will be released after close of market on Thursday, May 8 , 2014.  Following the announcement, Veracyte's management will host a live conference
View HTML
Toggle Summary Veracyte, Inc. Announces Fourth Quarter and Full-Year 2013 Financial Results, Provides 2014 Financial Outlook
-- 88% Growth in Full-Year 2013 Revenue, 92% Growth in Year-Over-Year FNA Volume ---- Increased Coverage and Reimbursement for Afirma® Gene Expression Classifier ---- Conference Call Today at 5 p.m. ET --
View HTML
Toggle Summary Veracyte, Inc. Appoints Julie A. Brooks as Executive Vice President, General Counsel and Secretary; and Andy Thorson as Executive Vice President, Corporate Strategy and Business Development
SOUTH SAN FRANCISCO, Calif. , March 17, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced the appointments of two executives to its management team. Julie A.
View HTML